Drug Trial Radar · NCT07222215
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
297
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Dec 1, 2029
Study completion Oct 1, 2030
Sponsor
- Lead sponsor
- Kristina A. FanucciAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stemline Therapeutics, Inc.; Johns Hopkins University; Translational Breast Cancer Research Consortium; Menarini Group; Gateway for Cancer Research; Terri Brodeur Breast Cancer Foundation
- First posted
- Oct 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Capecitabine (a type of fluoropyrimidine antimetabolite)
Conditions
- Estrogen-receptor-positive Breast Cancer
- Metastatic Breast Cancer
- Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- HER2- Breast Cancer
- ESR1 Gene Mutation
- ER Wildtype
- Breast Neoplasms
Interventions
CapecitabineDrug
A fluoropyrimidine carbamate, tablet taken orally, per standard of care.
ElacestrantDrug
A selective estrogen receptor degrader, tablet taken orally, per standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) in ESR1 mutant populationTime frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.
- Progression Free Survival (PFS) in intention to treat (ITT) populationTime frame: Tumor measurements are repeated every 3 cycles (each cycle is 21 days) for the first 9 cycles. After cycle 9 tumor measurements will be performed every 4 cycles.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.